- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04006691
Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)
A Phase 3b Multicenter Extension Trial Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper Urinary Tract Urothelial Carcinoma in Recurrent Patients From Trial TC-UT-03
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, single-arm, Phase 3b multicenter extension trial, designed to evaluate the efficacy and safety of UGN-101 administered to the UUT in patients who were treated in Trial TC-UT-03, found to be a CR at the PDE 1 Visit, and are subsequently found to have a documented recurrence of LG UTUC at FU.
Upon signing of informed consent, the patients will undergo their routine ureteroscopy to assess durability. A biopsy will be performed at Visit 0, if appropriate, to confirm evidence of tumor. If a high grade (HG) UTUC is confirmed by biopsy and/or cytology, the patient will be excluded from the retreatment trial. Eligible patients with confirmed LG non-invasive UTUC will be treated with 3 to 6 once-weekly instillations of UGN-101 in a retrograde fashion, per investigator's discretion.
Five weeks (± 1 week) following the last Investigational product (IP) treatment, the patient will be assessed for efficacy and safety at the PDE 2 Visit. At this visit, the patient will undergo ureteroscopy and any remaining lesions will be biopsied, and UUT urine wash will be collected for cytology.
Patients demonstrating CR at the PDE 2 Visit will undergo FU visits at 3, 6, 9, and 12 months (± 2 weeks) following the PDE 2 Visit.
The trial will be approximately 15 months, per patient: a 3- to 6-week treatment period, followed by 4 to 6 weeks post-treatment leading up to the PDE 2 Visit, and a 12-month FU post PDE 2 Visit. This trial will follow the Steering Committee, and a Data Monitoring Committee (DMC) has been assigned as established for the primary trial TC-UT-03.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ramat Gan, Israel, 52621
- Sheba Medical Center
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA - University of California, Los Angeles
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Florida
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- John Hopkins University
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Urology Center Las Vegas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main Inclusion Criteria:
- Patients with recurrent LG UTUC who were found to be CR at the PDE 1 Visit (in Trial TC-UT-03).
- Biopsy taken from 1 or more tumors located in the UUT shows LG urothelial carcinoma (up to 2 months before Visit 0). If there are tumors in both the kidney and the ureter, at least 1 biopsy should be taken from each location.
- Urine wash cytology sampled from the UUT documenting the absence of HG urothelial cancer.
- Patients must have adequate organ and bone marrow function as determined by routine laboratory tests.
- Patient has no active urinary tract infection (UTI) as confirmed by urine culture or urinalysis
Main Exclusion Criteria:
- Patient intends to be treated with systemic chemotherapy during the duration of the trial.
- Patient with urinary obstruction.
- Inability to deliver the IP to the UUT.
- Patient has any other medical or mental condition(s) that make(s) their participation in the trial unadvisable in the opinion of the treating investigator.
- Patient has a contraindication to mitomycin treatment, or known sensitivity to mitomycin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UGN-101 instillations
The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml.
3-6 once weekly intravesical instillations for the ablation treatment.
|
Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response (CR) rate
Time Frame: An average of 11 weeks
|
Complete response defined dichotomously as "Success" if CR was confirmed at the end of the treatment period (PDE 2 Visit), and "Failure" otherwise.
|
An average of 11 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-term durability of complete response (CR)
Time Frame: 3, 6, 9 and 12 months
|
This endpoint is defined only for those patients demonstrating CR at the PDE 2 Visit.
|
3, 6, 9 and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence (number of patients) of adverse events
Time Frame: 15 months
|
Adverse events (AEs) analyses will include only Treatment Emergent Adverse Events (TEAEs), namely, those events which started on the day of first trial IP administration or afterwards. The incidence (no. of patients) of TEAEs will be provided when broken down by System Organ Class (SOC) and by Preferred Term (PT) according to MedDRA dictionary;
|
15 months
|
Frequency (number of events) of adverse events
Time Frame: 15 months
|
Adverse events (AEs) analyses will include only Treatment Emergent Adverse Events (TEAEs), namely, those events which started on the day of first trial IP administration or afterwards. The Frequency (no. of patients) of TEAEs will be provided when broken down by System Organ Class (SOC) and by Preferred Term (PT) according to MedDRA dictionary;
|
15 months
|
Clinically meaningful changes in laboratory values of blood hematology, coagulation, liver and kidney function parameters and urinalysis
Time Frame: 15 months
|
Changes from baseline in laboratory values and incidence of measurements defined as Potentially Clinically Significant (PCS) will include the following: Complete blood count (CBC, including red blood, cell indices, and white blood cell differential, Platelet count), Creatinine, Blood urea nitrogen, Uric acid, Sodium, Potassium, Phosphorus, Calcium, serum glutamate oxaloacetate transaminase/aspartate aminotransferase (SGOT/AST), serum glutamate pyruvate transaminase/Alanine transaminase (SGPT/ALT), gamma-glutamyl transferase (GGT), Alkaline phosphatase, Total Bilirubin, Direct Bilirubin, Albumin, Total protein, Prothrombin Time and International Normalized Ratio, and Urinalysis (Specific gravity, power of hydrogen (pH), Glucose, Urobilinogen, Bilirubin, Blood, Protein, Nitrites, Leukocyte Esterase, Microscopic examination, Bacteriuria (if required) and White blood cells) |
15 months
|
Clinically meaningful changes in vital signs assessments values (blood pressure, pulse and temperature)
Time Frame: 15 months
|
Changes from baseline in vital signs assessments values and incidence of measurements of Potential Clinical Significance (PCS) will include blood pressure, pulse, and temperature
|
15 months
|
Clinically meaningful changes in full physical examination values including General appearance, Cardiovascular and Respiratory system, HEENT (head, eyes, ears, nose, and throat) and neck, Abdomen Extremities, Neurologic system, Skin and Urological system
Time Frame: 15 months
|
Any clinically-relevant changes occurring during the trial visit will be recorded in the AE sections of the case report form (CRF). Full general physical examination will be done on visits 0, 7, and 11 Urology-oriented physical examinations will be done on visits 0, 7, 8, 9, 10, and 11. Full physical examination findings are composite outcome measure consisting of multiple measures: General appearance, Cardiovascular system, Respiratory system, HEENT (head, eyes, ears, nose, and throat) and neck, Abdomen Extremities and Neurologic system Skin Urology-Oriented physical examination findings are composite outcome measure consisting of multiple measures: Urethral meatus, Perineal skin and mucus membranes Scrotum and testes (for male patients), Lymphadenopathy, Rectal examination (Screening visit only) Bimanual examination (female patients - Screening visit only) |
15 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ifat Klein, PhD, UroGen Pharma
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Carcinoma, Transitional Cell
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Alkylating Agents
- Antibiotics, Antineoplastic
- Mitomycins
- Mitomycin
Other Study ID Numbers
- TC-UT-03/E
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
Clinical Trials on UGN-101 instillations
-
UroGen Pharma Ltd.CompletedCarcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal PelvisUnited States, Israel
-
UroGen Pharma Ltd.RecruitingBladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of BladderUnited States, Italy, Spain
-
National Multiple Sclerosis CenterTerminatedInterstitial Cystitis | Painful Bladder SyndromeBelgium
-
UroGen Pharma Ltd.RecruitingCarcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal PelvisUnited States
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruiting
-
UroGen Pharma Ltd.Active, not recruitingBladder Cancer | Urothelial Carcinoma Bladder | Urothelial CarcinomaUnited States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
-
UroGen Pharma Ltd.CompletedBladder Cancer | Urothelial Carcinoma Bladder | Urothelial CarcinomaUnited States, Israel
-
UroGen Pharma Ltd.CompletedBladder Cancer | Urothelial Carcinoma Bladder | Urothelial CarcinomaUnited States
-
UroGen Pharma Ltd.Not yet recruitingBladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
-
The University of Western AustraliaRoyal Perth Hospital; Fiona Stanley Hospital; Perth Urology ClinicCompletedSpinal Cord InjuriesAustralia